Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, multi-center, open-label, Phase 2 study to determine the efficacy and safety of JCAR015 in adult subjects with B-cell ALL. The study is divided into two sequential parts, Part A and Part B; subjects will be screened and will provide informed consent before initiating any study procedures in Part A of the study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02973191
Study type Interventional
Source Celgene
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date December 20, 2016
Completion date January 24, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05026229 - A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL N/A
Recruiting NCT05024357 - A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL N/A
Completed NCT03545659 - Childhood Acute Lymphoblastic Leukaemia: Follow-Up
Completed NCT03985826 - Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
Recruiting NCT05660473 - Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Phase 2
Withdrawn NCT03888534 - Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) Phase 1
Completed NCT03743246 - A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1/Phase 2
Recruiting NCT05968963 - Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation N/A
Active, not recruiting NCT01429610 - Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia Phase 2
Completed NCT03384654 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Phase 2
Completed NCT01317940 - Nutrition and Body Composition in Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02454270 - A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies Phase 1
Completed NCT01331590 - Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Phase 0
Completed NCT04456959 - InO - A Retrospective Study of UK Patients With Leukaemia
Recruiting NCT03462095 - De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL) N/A
Completed NCT01386619 - NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Phase 1/Phase 2
Withdrawn NCT03985215 - The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives
Recruiting NCT02328950 - A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome N/A
Recruiting NCT05873322 - Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
Recruiting NCT02390752 - Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... Phase 1